-
1
-
-
36849010167
-
Adaptive immunity maintains occult cancer in an equilibrium state
-
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907.
-
(2007)
Nature
, vol.450
, pp. 903-907
-
-
Koebel, C.M.1
Vermi, W.2
Swann, J.B.3
Zerafa, N.4
Rodig, S.J.5
Old, L.J.6
-
2
-
-
33646755569
-
Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity
-
Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90: 1-50.
-
(2006)
Adv Immunol
, vol.90
, pp. 1-50
-
-
Smyth, M.J.1
Dunn, G.P.2
Schreiber, R.D.3
-
3
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
5
-
-
58149307496
-
Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy
-
Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009; 58: 317-324.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 317-324
-
-
Baxevanis, C.N.1
Perez, S.A.2
Papamichail, M.3
-
6
-
-
17144417748
-
Dendritic cells as therapeutic vaccines against cancer
-
Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306.
-
(2005)
Nat Rev Immunol
, vol.5
, pp. 296-306
-
-
Banchereau, J.1
Palucka, A.K.2
-
7
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
-
8
-
-
51349123892
-
Cancer immunotherapy by dendritic cells
-
Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-383.
-
(2008)
Immunity
, vol.29
, pp. 372-383
-
-
Melief, C.J.1
-
9
-
-
77951259112
-
Building on dendritic cell subsets to improve cancer vaccines
-
Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J. Building on dendritic cell subsets to improve cancer vaccines. Curr Opin Immunol 2010; 22: 258-263.
-
(2010)
Curr Opin Immunol
, vol.22
, pp. 258-263
-
-
Palucka, K.1
Ueno, H.2
Zurawski, G.3
Fay, J.4
Banchereau, J.5
-
10
-
-
73149117784
-
Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: A systematic review
-
Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-1438.
-
(2009)
Arch Dermatol
, vol.145
, pp. 1431-1438
-
-
Love, W.E.1
Bernhard, J.D.2
Bordeaux, J.S.3
-
11
-
-
0036858838
-
Depletion of CD25\+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens
-
Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25\+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002; 32: 3267-3275.
-
(2002)
Eur J Immunol
, vol.32
, pp. 3267-3275
-
-
Golgher, D.1
Jones, E.2
Powrie, F.3
Elliott, T.4
Gallimore, A.5
-
12
-
-
0035893387
-
Depletion of CD25(\+) CD4(\+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced CD8(\+) T-cell-dependent immune defense of B16 melanoma
-
Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(\+) CD4(\+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(\+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001; 61: 8643-8646.
-
(2001)
Cancer Res
, vol.61
, pp. 8643-8646
-
-
Steitz, J.1
Bruck, J.2
Lenz, J.3
Knop, J.4
Tuting, T.5
-
13
-
-
33745820353
-
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4\+ and CD8\+ regulatory T cells
-
Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4\+ and CD8\+ regulatory T cells. J Immunol 2006; 177: 896-904.
-
(2006)
J Immunol
, vol.177
, pp. 896-904
-
-
Jarnicki, A.G.1
Lysaght, J.2
Todryk, S.3
Mills, K.H.4
-
14
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
15
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
16
-
-
84876248304
-
Endocrine side effects induced by immune checkpoint inhibitors
-
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98: 1361-1375.
-
(2013)
J Clin Endocrinol Metab
, vol.98
, pp. 1361-1375
-
-
Corsello, S.M.1
Barnabei, A.2
Marchetti, P.3
De Vecchis, L.4
Salvatori, R.5
Torino, F.6
-
17
-
-
8544242704
-
Regulatory T cells: Friend or foe in immunity to infection?
-
Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-855.
-
(2004)
Nat Rev Immunol
, vol.4
, pp. 841-855
-
-
Mills, K.H.1
-
18
-
-
0037364804
-
Natural versus adaptive regulatory T cells
-
Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253-257.
-
(2003)
Nat Rev Immunol
, vol.3
, pp. 253-257
-
-
Bluestone, J.A.1
Abbas, A.K.2
-
19
-
-
0035874949
-
Regulatory CD4(\+)CD25(\+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
-
Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al. Regulatory CD4(\+)CD25(\+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer research 2001; 61: 4766-4772.
-
(2001)
Cancer Research
, vol.61
, pp. 4766-4772
-
-
Woo, E.Y.1
Chu, C.S.2
Goletz, T.J.3
Schlienger, K.4
Yeh, H.5
Coukos, G.6
-
20
-
-
77951626075
-
Regulatory T cells in cancer
-
Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res 2010; 107: 57-117.
-
(2010)
Adv Cancer Res
, vol.107
, pp. 57-117
-
-
Mougiakakos, D.1
Choudhury, A.2
Lladser, A.3
Kiessling, R.4
Johansson, C.C.5
-
21
-
-
32644461994
-
Regulatory T cells and Toll-like receptors in tumor immunity
-
Wang RF, Peng G, Wang HY. Regulatory T cells and Toll-like receptors in tumor immunity. Semin Immunol 2006; 18: 136-142.
-
(2006)
Semin Immunol
, vol.18
, pp. 136-142
-
-
Wang, R.F.1
Peng, G.2
Wang, H.Y.3
-
22
-
-
0025006629
-
Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide
-
Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990; 50: 5358-5364.
-
(1990)
Cancer Res
, vol.50
, pp. 5358-5364
-
-
Hoon, D.S.1
Foshag, L.J.2
Nizze, A.S.3
Bohman, R.4
Morton, D.L.5
-
23
-
-
42649136634
-
Transient T cell depletion causes regression of melanoma metastases
-
Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008; 6: 12.
-
(2008)
J Transl Med
, vol.6
, pp. 12
-
-
Rasku, M.A.1
Clem, A.L.2
Telang, S.3
Taft, B.4
Gettings, K.5
Gragg, H.6
-
24
-
-
70350496784
-
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells
-
Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009; 1174: 99-106.
-
(2009)
Ann NY Acad Sci
, vol.1174
, pp. 99-106
-
-
Rech, A.J.1
Vonderheide, R.H.2
-
25
-
-
84870444019
-
Depletion of Tregs in vivo: A promising approach to enhance antitumor immunity without autoimmunity
-
Morita R, Hirohashi Y, Sato N. Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity. Immunotherapy 2012; 4: 1103-1105.
-
(2012)
Immunotherapy
, vol.4
, pp. 1103-1105
-
-
Morita, R.1
Hirohashi, Y.2
Sato, N.3
-
26
-
-
25844517914
-
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumorinfiltrating Foxp3\+CD25\+CD4\+ regulatory T cells
-
Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumorinfiltrating Foxp3\+CD25\+CD4\+ regulatory T cells. J Exp Med 2005; 202: 885-891.
-
(2005)
J Exp Med
, vol.202
, pp. 885-891
-
-
Ko, K.1
Yamazaki, S.2
Nakamura, K.3
Nishioka, T.4
Hirota, K.5
Yamaguchi, T.6
-
27
-
-
77955515915
-
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
-
Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010; 59: 1367-1377.
-
(2010)
Cancer Immunol Immunother
, vol.59
, pp. 1367-1377
-
-
Coe, D.1
Begom, S.2
Addey, C.3
White, M.4
Dyson, J.5
Chai, J.G.6
-
28
-
-
79952193038
-
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
-
Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470: 548-553.
-
(2011)
Nature
, vol.470
, pp. 548-553
-
-
Tan, W.1
Zhang, W.2
Strasner, A.3
Grivennikov, S.4
Cheng, J.Q.5
Hoffman, R.M.6
-
29
-
-
67349250445
-
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform
-
Amendola M, Passerini L, Pucci F, Gentner B, Bacchetta R, Naldini L. Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther 2009; 17: 1039-1052.
-
(2009)
Mol Ther
, vol.17
, pp. 1039-1052
-
-
Amendola, M.1
Passerini, L.2
Pucci, F.3
Gentner, B.4
Bacchetta, R.5
Naldini, L.6
-
30
-
-
78149486215
-
A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice
-
Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 2010; 185: 5150-5159.
-
(2010)
J Immunol
, vol.185
, pp. 5150-5159
-
-
Casares, N.1
Rudilla, F.2
Arribillaga, L.3
Llopiz, D.4
Riezu-Boj, J.I.5
Lozano, T.6
-
31
-
-
44049101771
-
Foxp3 expression in human cancer cells
-
Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T et al. Foxp3 expression in human cancer cells. J Transl Med 2008; 6: 19.
-
(2008)
J Transl Med
, vol.6
, pp. 19
-
-
Karanikas, V.1
Speletas, M.2
Zamanakou, M.3
Kalala, F.4
Loules, G.5
Kerenidi, T.6
-
32
-
-
8544281696
-
Bone marrow is a reservoir for CD4\+CD25\+ regulatory T cells that traffic through CXCL12/CXCR4 signals
-
Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P et al. Bone marrow is a reservoir for CD4\+CD25\+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451-8455.
-
(2004)
Cancer Res
, vol.64
, pp. 8451-8455
-
-
Zou, L.1
Barnett, B.2
Safah, H.3
Larussa, V.F.4
Evdemon-Hogan, M.5
Mottram, P.6
-
33
-
-
4644237613
-
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
-
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
-
(2004)
Nat Med
, vol.10
, pp. 942-949
-
-
Curiel, T.J.1
Coukos, G.2
Zou, L.3
Alvarez, X.4
Cheng, P.5
Mottram, P.6
-
34
-
-
84871718282
-
Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer
-
Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 2012; 1: 152-161.
-
(2012)
Oncoimmunology
, vol.1
, pp. 152-161
-
-
Zhao, E.1
Wang, L.2
Dai, J.3
Kryczek, I.4
Wei, S.5
Vatan, L.6
-
35
-
-
54049134747
-
Subsets of myeloid-derived suppressor cells in tumor-bearing mice
-
Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-5802.
-
(2008)
J Immunol
, vol.181
, pp. 5791-5802
-
-
Youn, J.I.1
Nagaraj, S.2
Collazo, M.3
Gabrilovich, D.I.4
-
36
-
-
61349100687
-
Myeloid-derived suppressor cells as regulators of the immune system
-
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
-
(2009)
Nat Rev Immunol
, vol.9
, pp. 162-174
-
-
Gabrilovich, D.I.1
Nagaraj, S.2
-
37
-
-
34249300128
-
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
-
Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-4513.
-
(2007)
Cancer Res
, vol.67
, pp. 4507-4513
-
-
Sinha, P.1
Clements, V.K.2
Fulton, A.M.3
Ostrand-Rosenberg, S.4
-
38
-
-
65249138393
-
Myeloid-derived suppressor cells: Linking inflammation and cancer
-
Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
-
(2009)
J Immunol
, vol.182
, pp. 4499-4506
-
-
Ostrand-Rosenberg, S.1
Sinha, P.2
-
39
-
-
77951258918
-
Myeloid-derived suppressor cell heterogeneity and subset definition
-
Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-244.
-
(2010)
Curr Opin Immunol
, vol.22
, pp. 238-244
-
-
Peranzoni, E.1
Zilio, S.2
Marigo, I.3
Dolcetti, L.4
Zanovello, P.5
Mandruzzato, S.6
-
40
-
-
67149115417
-
Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Tolllike receptor 4
-
Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Tolllike receptor 4. J Leukocyte Biol 2009; 85: 996-1004.
-
(2009)
J Leukocyte Biol
, vol.85
, pp. 996-1004
-
-
Bunt, S.K.1
Clements, V.K.2
Hanson, E.M.3
Sinha, P.4
Ostrand-Rosenberg, S.5
-
41
-
-
34250359119
-
MyD88-dependent expansion of an immature GR-1(\+)CD11b(\+) population induces T cell suppression and Th2 polarization in sepsis
-
Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM et al. MyD88-dependent expansion of an immature GR-1(\+)CD11b(\+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204: 1463-1474.
-
(2007)
J Exp Med
, vol.204
, pp. 1463-1474
-
-
Delano, M.J.1
Scumpia, P.O.2
Weinstein, J.S.3
Coco, D.4
Nagaraj, S.5
Kelly-Scumpia, K.M.6
-
42
-
-
0032533478
-
Apoptotic death of CD8\+ T lymphocytes after immunization: Induction of a suppressive population of Mac-1\+/Gr-1\+ cells
-
Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA et al. Apoptotic death of CD8\+ T lymphocytes after immunization: induction of a suppressive population of Mac-1\+/Gr-1\+ cells. J Immunol 1998; 161: 5313-5320.
-
(1998)
J Immunol
, vol.161
, pp. 5313-5320
-
-
Bronte, V.1
Wang, M.2
Overwijk, W.W.3
Surman, D.R.4
Pericle, F.5
Rosenberg, S.A.6
-
43
-
-
79959271214
-
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
-
Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011; 117: 6532-6541.
-
(2011)
Blood
, vol.117
, pp. 6532-6541
-
-
Hoechst, B.1
Gamrekelashvili, J.2
Manns, M.P.3
Greten, T.F.4
Korangy, F.5
-
44
-
-
48549085973
-
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells
-
Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68: 5439-5449.
-
(2008)
Cancer Res
, vol.68
, pp. 5439-5449
-
-
Serafini, P.1
Mgebroff, S.2
Noonan, K.3
Borrello, I.4
-
45
-
-
34548805636
-
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response
-
Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-983.
-
(2007)
J Immunol
, vol.179
, pp. 977-983
-
-
Sinha, P.1
Clements, V.K.2
Bunt, S.K.3
Albelda, S.M.4
Ostrand-Rosenberg, S.5
-
46
-
-
31544446571
-
Gr-1\+CD115\+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
-
Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J et al. Gr-1\+CD115\+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131.
-
(2006)
Cancer Res
, vol.66
, pp. 1123-1131
-
-
Huang, B.1
Pan, P.Y.2
Li, Q.3
Sato, A.I.4
Levy, D.E.5
Bromberg, J.6
-
47
-
-
77955549860
-
Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity
-
Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-1600.
-
(2010)
Cancer Immunol Immunother
, vol.59
, pp. 1593-1600
-
-
Ostrand-Rosenberg, S.1
-
48
-
-
79952281795
-
Improving cancer immunotherapy by targeting tumorinduced immune suppression
-
Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumorinduced immune suppression. Cancer Metastasis Rev 2011; 30: 125-140.
-
(2011)
Cancer Metastasis Rev
, vol.30
, pp. 125-140
-
-
Stewart, T.J.1
Smyth, M.J.2
-
49
-
-
0035339932
-
Mechanism of immune dysfunction in cancer mediated by immature Gr-1\+ myeloid cells
-
Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1\+ myeloid cells. J Immunol 2001; 166: 5398-5406.
-
(2001)
J Immunol
, vol.166
, pp. 5398-5406
-
-
Gabrilovich, D.I.1
Velders, M.P.2
Sotomayor, E.M.3
Kast, W.M.4
-
50
-
-
33749461167
-
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
-
Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307.
-
(2006)
Cancer Res
, vol.66
, pp. 9299-9307
-
-
Mirza, N.1
Fishman, M.2
Fricke, I.3
Dunn, M.4
Neuger, A.M.5
Frost, T.J.6
-
51
-
-
36348989162
-
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells
-
Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007; 67: 11021-11028.
-
(2007)
Cancer Res
, vol.67
, pp. 11021-11028
-
-
Nefedova, Y.1
Fishman, M.2
Sherman, S.3
Wang, X.4
Beg, A.A.5
Gabrilovich, D.I.6
-
52
-
-
2342634392
-
Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3
-
Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 2004; 53: 422-430.
-
(2004)
Cancer Immunol Immunother
, vol.53
, pp. 422-430
-
-
Lathers, D.M.1
Clark, J.I.2
Achille, N.J.3
Young, M.R.4
-
53
-
-
68849128500
-
Therapeutic targeting of myeloid-derived suppressor cells
-
Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9: 470-481.
-
(2009)
Curr Opin Pharmacol
, vol.9
, pp. 470-481
-
-
Ugel, S.1
Delpozzo, F.2
Desantis, G.3
Papalini, F.4
Simonato, F.5
Sonda, N.6
-
54
-
-
25144466458
-
Gemcitabine selectively eliminates splenic Gr-1\+/CD11b\+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
-
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1\+/CD11b\+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6713-6721
-
-
Suzuki, E.1
Kapoor, V.2
Jassar, A.S.3
Kaiser, L.R.4
Albelda, S.M.5
-
55
-
-
77951754469
-
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained
-
Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70: 3526-3536.
-
(2010)
Cancer Res
, vol.70
, pp. 3526-3536
-
-
Ko, J.S.1
Rayman, P.2
Ireland, J.3
Swaidani, S.4
Li, G.5
Bunting, K.D.6
-
56
-
-
63549105681
-
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
-
Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2148-2157
-
-
Ko, J.S.1
Zea, A.H.2
Rini, B.I.3
Ireland, J.L.4
Elson, P.5
Cohen, P.6
-
57
-
-
65549141834
-
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies
-
Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-2522.
-
(2009)
Cancer Res
, vol.69
, pp. 2514-2522
-
-
Ozao-Choy, J.1
Ma, G.2
Kao, J.3
Wang, G.X.4
Meseck, M.5
Sung, M.6
-
58
-
-
77951086882
-
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity
-
Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-3061.
-
(2010)
Cancer Res
, vol.70
, pp. 3052-3061
-
-
Vincent, J.1
Mignot, G.2
Chalmin, F.3
Ladoire, S.4
Bruchard, M.5
Chevriaux, A.6
-
59
-
-
77956680680
-
A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers
-
Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16: 4583-4594.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4583-4594
-
-
Kodumudi, K.N.1
Woan, K.2
Gilvary, D.L.3
Sahakian, E.4
Wei, S.5
Djeu, J.Y.6
-
60
-
-
0042591427
-
All-transretinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination
-
Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R et al. All-transretinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63: 4441-4449.
-
(2003)
Cancer Res
, vol.63
, pp. 4441-4449
-
-
Kusmartsev, S.1
Cheng, F.2
Yu, B.3
Nefedova, Y.4
Sotomayor, E.5
Lush, R.6
-
61
-
-
29244474606
-
Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis
-
Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005; 65: 11743-11751.
-
(2005)
Cancer Res
, vol.65
, pp. 11743-11751
-
-
Sinha, P.1
Clements, V.K.2
Ostrand-Rosenberg, S.3
-
62
-
-
25844503817
-
Tumor immunity: A balancing act between T cell activation, macrophage activation and tumor-induced immune suppression
-
Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005; 54: 1137-1142.
-
(2005)
Cancer Immunol Immunother
, vol.54
, pp. 1137-1142
-
-
Sinha, P.1
Clements, V.K.2
Miller, S.3
Ostrand-Rosenberg, S.4
-
63
-
-
77949718839
-
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer
-
Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010; 16: 1812-1823.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1812-1823
-
-
Nagaraj, S.1
Youn, J.I.2
Weber, H.3
Iclozan, C.4
Lu, L.5
Cotter, M.J.6
-
64
-
-
79953324535
-
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells
-
Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71: 2664-2674.
-
(2011)
Cancer Res
, vol.71
, pp. 2664-2674
-
-
Fujita, M.1
Kohanbash, G.2
Fellows-Mayle, W.3
Hamilton, R.L.4
Komohara, Y.5
Decker, S.A.6
-
65
-
-
81555228400
-
Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells
-
Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498-5505.
-
(2011)
Blood
, vol.118
, pp. 5498-5505
-
-
Obermajer, N.1
Muthuswamy, R.2
Lesnock, J.3
Edwards, R.P.4
Kalinski, P.5
-
66
-
-
20144375187
-
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination
-
De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005; 102: 4185-4190.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 4185-4190
-
-
De Santo, C.1
Serafini, P.2
Marigo, I.3
Dolcetti, L.4
Bolla, M.5
Del Soldato, P.6
-
67
-
-
40049088602
-
The inflammatory microenvironment in tumor progression: The role of tumor-associated macrophages
-
Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory microenvironment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66: 1-9.
-
(2008)
Crit Rev Oncol Hematol
, vol.66
, pp. 1-9
-
-
Allavena, P.1
Sica, A.2
Solinas, G.3
Porta, C.4
Mantovani, A.5
-
68
-
-
70350728931
-
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
-
Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-1073.
-
(2009)
J Leukoc Biol
, vol.86
, pp. 1065-1073
-
-
Solinas, G.1
Germano, G.2
Mantovani, A.3
Allavena, P.4
-
69
-
-
34248172324
-
Altered macrophage differentiation and immune dysfunction in tumor development
-
Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-1166.
-
(2007)
J Clin Invest
, vol.117
, pp. 1155-1166
-
-
Sica, A.1
Bronte, V.2
-
70
-
-
48349102876
-
Macrophage polarization in tumour progression
-
Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-355.
-
(2008)
Semin Cancer Biol
, vol.18
, pp. 349-355
-
-
Sica, A.1
Larghi, P.2
Mancino, A.3
Rubino, L.4
Porta, C.5
Totaro, M.G.6
-
71
-
-
35548982639
-
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
-
Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-475.
-
(2007)
Cell
, vol.131
, pp. 463-475
-
-
Fischer, C.1
Jonckx, B.2
Mazzone, M.3
Zacchigna, S.4
Loges, S.5
Pattarini, L.6
-
72
-
-
77954229219
-
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects
-
Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010; 16: 3420-3430.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3420-3430
-
-
Zhang, W.1
Zhu, X.D.2
Sun, H.C.3
Xiong, Y.Q.4
Zhuang, P.Y.5
Xu, H.X.6
-
73
-
-
77952389941
-
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment
-
Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA 2010; 107: 8363-8368.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 8363-8368
-
-
Ahn, G.O.1
Tseng, D.2
Liao, C.H.3
Dorie, M.J.4
Czechowicz, A.5
Brown, J.M.6
-
74
-
-
70350705942
-
The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment
-
Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 2009; 11: 1235-1242.
-
(2009)
Neoplasia
, vol.11
, pp. 1235-1242
-
-
Mizutani, K.1
Sud, S.2
McGregor, N.A.3
Martinovski, G.4
Rice, B.T.5
Craig, M.J.6
-
75
-
-
79960411324
-
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
-
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-225.
-
(2011)
Nature
, vol.475
, pp. 222-225
-
-
Qian, B.Z.1
Li, J.2
Zhang, H.3
Kitamura, T.4
Zhang, J.5
Campion, L.R.6
-
76
-
-
80052746486
-
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
-
Zhu X, Fujita M, Snyder LA, Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 2011; 104: 83-92.
-
(2011)
J Neurooncol
, vol.104
, pp. 83-92
-
-
Zhu, X.1
Fujita, M.2
Snyder, L.A.3
Okada, H.4
-
77
-
-
66049154097
-
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
-
Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009; 206: 1089-1102.
-
(2009)
J Exp Med
, vol.206
, pp. 1089-1102
-
-
Kubota, Y.1
Takubo, K.2
Shimizu, T.3
Ohno, H.4
Kishi, K.5
Shibuya, M.6
-
78
-
-
70949104409
-
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia
-
Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 2009; 8: 3151-3161.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 3151-3161
-
-
Manthey, C.L.1
Johnson, D.L.2
Illig, C.R.3
Tuman, R.W.4
Zhou, Z.5
Baker, J.F.6
-
79
-
-
33646243569
-
Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts
-
Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006; 66: 4349-4356.
-
(2006)
Cancer Res
, vol.66
, pp. 4349-4356
-
-
Paulus, P.1
Stanley, E.R.2
Schafer, R.3
Abraham, D.4
Aharinejad, S.5
-
80
-
-
84858339905
-
Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development
-
Pyonteck SM, Gadea BB, Wang HW, Gocheva V, Hunter KE, Tang LH et al. Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene 2012; 31: 1459-1467.
-
(2012)
Oncogene
, vol.31
, pp. 1459-1467
-
-
Pyonteck, S.M.1
Gadea, B.B.2
Wang, H.W.3
Gocheva, V.4
Hunter, K.E.5
Tang, L.H.6
-
81
-
-
49749146393
-
Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages
-
Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008; 99: 1595-1602.
-
(2008)
Cancer Sci
, vol.99
, pp. 1595-1602
-
-
Hiraoka, K.1
Zenmyo, M.2
Watari, K.3
Iguchi, H.4
Fotovati, A.5
Kimura, Y.N.6
-
82
-
-
42249115328
-
Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma
-
Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 2008; 7: 788-799.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 788-799
-
-
Miselis, N.R.1
Wu, Z.J.2
Van Rooijen, N.3
Kane, A.B.4
-
83
-
-
33746926292
-
Clodronate-liposome-mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach
-
Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006; 95: 272-281.
-
(2006)
Br J Cancer
, vol.95
, pp. 272-281
-
-
Zeisberger, S.M.1
Odermatt, B.2
Marty, C.3
Zehnder-Fjallman, A.H.4
Ballmer-Hofer, K.5
Schwendener, R.A.6
-
84
-
-
34548434775
-
Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages
-
Suzuki T, Franchi L, Toma C, Ashida H, Ogawa M, Yoshikawa Y et al. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog 2007; 3: e111.
-
(2007)
PLoS Pathog
, vol.3
, pp. e111
-
-
Suzuki, T.1
Franchi, L.2
Toma, C.3
Ashida, H.4
Ogawa, M.5
Yoshikawa, Y.6
-
85
-
-
68549104285
-
Targeting tumorassociated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta
-
Nagai T, Tanaka M, Tsuneyoshi Y, Xu B, Michie SA, Hasui K et al. Targeting tumorassociated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother 2009; 58: 1577-1586.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 1577-1586
-
-
Nagai, T.1
Tanaka, M.2
Tsuneyoshi, Y.3
Xu, B.4
Michie, S.A.5
Hasui, K.6
-
86
-
-
73649093148
-
Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages
-
Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 2009; 69: 9395-9403.
-
(2009)
Cancer Res
, vol.69
, pp. 9395-9403
-
-
Puig-Kroger, A.1
Sierra-Filardi, E.2
Dominguez-Soto, A.3
Samaniego, R.4
Corcuera, M.T.5
Gomez-Aguado, F.6
-
87
-
-
65549129226
-
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells
-
Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506-2513.
-
(2009)
Cancer Res
, vol.69
, pp. 2506-2513
-
-
Xin, H.1
Zhang, C.2
Herrmann, A.3
Du, Y.4
Figlin, R.5
Yu, H.6
-
88
-
-
77957244887
-
The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages
-
Edwards JP, Emens LA. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages. Int Immunopharmacol 2010; 10: 1220-1228.
-
(2010)
Int Immunopharmacol
, vol.10
, pp. 1220-1228
-
-
Edwards, J.P.1
Emens, L.A.2
-
89
-
-
35448979864
-
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients
-
Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67: 9630-9636.
-
(2007)
Cancer Res
, vol.67
, pp. 9630-9636
-
-
Hussain, S.F.1
Kong, L.Y.2
Jordan, J.3
Conrad, C.4
Madden, T.5
Fokt, I.6
-
90
-
-
78650218768
-
Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages
-
Fujiwara Y, Komohara Y, Ikeda T, Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci 2011; 102: 206-211.
-
(2011)
Cancer Sci
, vol.102
, pp. 206-211
-
-
Fujiwara, Y.1
Komohara, Y.2
Ikeda, T.3
Takeya, M.4
-
91
-
-
80053516019
-
Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3
-
Fujiwara Y, Komohara Y, Kudo R, Tsurushima K, Ohnishi K, Ikeda T et al. Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3. Oncol Rep 2011; 26: 1533-1537.
-
(2011)
Oncol Rep
, vol.26
, pp. 1533-1537
-
-
Fujiwara, Y.1
Komohara, Y.2
Kudo, R.3
Tsurushima, K.4
Ohnishi, K.5
Ikeda, T.6
-
92
-
-
11844277698
-
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease
-
Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174: 636-645.
-
(2005)
J Immunol
, vol.174
, pp. 636-645
-
-
Sinha, P.1
Clements, V.K.2
Ostrand-Rosenberg, S.3
-
93
-
-
84855846598
-
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology
-
Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012; 119: 411-421.
-
(2012)
Blood
, vol.119
, pp. 411-421
-
-
Pello, O.M.1
De Pizzol, M.2
Mirolo, M.3
Soucek, L.4
Zammataro, L.5
Amabile, A.6
-
94
-
-
79957579025
-
Alternative activation of macrophages by IL-4 requires SHIP degradation
-
Weisser SB, McLarren KW, Voglmaier N, van Netten-Thomas CJ, Antov A, Flavell RA et al. Alternative activation of macrophages by IL-4 requires SHIP degradation. Eur J Immunol 2011; 41: 1742-1753.
-
(2011)
Eur J Immunol
, vol.41
, pp. 1742-1753
-
-
Weisser, S.B.1
McLarren, K.W.2
Voglmaier, N.3
Van Netten-Thomas, C.J.4
Antov, A.5
Flavell, R.A.6
-
95
-
-
79960021457
-
Kruppel-like factor 4 regulates macrophage polarization
-
Liao X, Sharma N, Kapadia F, Zhou G, Lu Y, Hong H et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest 2011; 121: 2736-2749.
-
(2011)
J Clin Invest
, vol.121
, pp. 2736-2749
-
-
Liao, X.1
Sharma, N.2
Kapadia, F.3
Zhou, G.4
Lu, Y.5
Hong, H.6
-
96
-
-
77957350018
-
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression
-
Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 2010; 70: 7465-7475.
-
(2010)
Cancer Res
, vol.70
, pp. 7465-7475
-
-
Doedens, A.L.1
Stockmann, C.2
Rubinstein, M.P.3
Liao, D.4
Zhang, N.5
Denardo, D.G.6
-
97
-
-
76749096776
-
An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis
-
Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R et al. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res 2010; 70: 1323-1333.
-
(2010)
Cancer Res
, vol.70
, pp. 1323-1333
-
-
Zabuawala, T.1
Taffany, D.A.2
Sharma, S.M.3
Merchant, A.4
Adair, B.5
Srinivasan, R.6
-
98
-
-
84863232885
-
Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway
-
Chen W, Ma T, Shen XN, Xia XF, Xu GD, Bai XL et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res 2012; 72: 1363-1372.
-
(2012)
Cancer Res
, vol.72
, pp. 1363-1372
-
-
Chen, W.1
Ma, T.2
Shen, X.N.3
Xia, X.F.4
Xu, G.D.5
Bai, X.L.6
-
99
-
-
79954571318
-
Cell surface signaling molecules in the control of immune responses: A tide model
-
Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 2011; 34: 466-478.
-
(2011)
Immunity
, vol.34
, pp. 466-478
-
-
Zhu, Y.1
Yao, S.2
Chen, L.3
-
100
-
-
0038273853
-
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
-
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562-567.
-
(2003)
Nat Med
, vol.9
, pp. 562-567
-
-
Curiel, T.J.1
Wei, S.2
Dong, H.3
Alvarez, X.4
Cheng, P.5
Mottram, P.6
-
101
-
-
77958067744
-
Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer
-
Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 2010; 59: 1707-1714.
-
(2010)
Cancer Immunol Immunother
, vol.59
, pp. 1707-1714
-
-
Jiang, J.1
Zhu, Y.2
Wu, C.3
Shen, Y.4
Wei, W.5
Chen, L.6
-
102
-
-
33645853780
-
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
-
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871-881.
-
(2006)
J Exp Med
, vol.203
, pp. 871-881
-
-
Kryczek, I.1
Zou, L.2
Rodriguez, P.3
Zhu, G.4
Wei, S.5
Mottram, P.6
-
103
-
-
84881423899
-
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses
-
Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R et al. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res 2013; 73: 4820-4829.
-
(2013)
Cancer Res
, vol.73
, pp. 4820-4829
-
-
Dangaj, D.1
Lanitis, E.2
Zhao, A.3
Joshi, S.4
Cheng, Y.5
Sandaltzopoulos, R.6
-
104
-
-
84873372202
-
Advances in targeting cell surface signalling molecules for immune modulation
-
Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013; 12: 130-146.
-
(2013)
Nat Rev Drug Discov
, vol.12
, pp. 130-146
-
-
Yao, S.1
Zhu, Y.2
Chen, L.3
-
105
-
-
78449244037
-
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
-
Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507.
-
(2010)
Semin Oncol
, vol.37
, pp. 499-507
-
-
Di Giacomo, A.M.1
Biagioli, M.2
Maio, M.3
-
106
-
-
55949083407
-
Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment
-
Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5275-5283
-
-
Fong, L.1
Small, E.J.2
-
107
-
-
77649136167
-
Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma
-
Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 2010; 16: 1662-1672.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1662-1672
-
-
Ralph, C.1
Elkord, E.2
Burt, D.J.3
O'Dwyer, J.F.4
Austin, E.B.5
Stern, P.L.6
-
108
-
-
77955292303
-
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
-
Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 2010; 28: 3485-3490.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3485-3490
-
-
Chung, K.Y.1
Gore, I.2
Fong, L.3
Venook, A.4
Beck, S.B.5
Dorazio, P.6
-
109
-
-
84879625854
-
New checkpoint inhibitors ride the immunotherapy tsunami
-
Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 2013; 12: 489-492.
-
(2013)
Nat Rev Drug Discov
, vol.12
, pp. 489-492
-
-
Mullard, A.1
-
110
-
-
84863115998
-
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
-
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72: 917-927.
-
(2012)
Cancer Res
, vol.72
, pp. 917-927
-
-
Woo, S.R.1
Turnis, M.E.2
Goldberg, M.V.3
Bankoti, J.4
Selby, M.5
Nirschl, C.J.6
-
112
-
-
42449102990
-
Up on the tightrope: Natural killer cell activation and inhibition
-
Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
-
(2008)
Nat Immunol
, vol.9
, pp. 495-502
-
-
Lanier, L.L.1
-
113
-
-
77957744369
-
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
-
Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194.
-
(2010)
J Exp Med
, vol.207
, pp. 2187-2194
-
-
Sakuishi, K.1
Apetoh, L.2
Sullivan, J.M.3
Blazar, B.R.4
Kuchroo, V.K.5
Anderson, A.C.6
-
114
-
-
77957723967
-
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8\+ T cell dysfunction in melanoma patients
-
Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8\+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186.
-
(2010)
J Exp Med
, vol.207
, pp. 2175-2186
-
-
Fourcade, J.1
Sun, Z.2
Benallaoua, M.3
Guillaume, P.4
Luescher, I.F.5
Sander, C.6
-
115
-
-
84862317836
-
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
-
Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 2012; 61: 917-926.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 917-926
-
-
Waickman, A.T.1
Alme, A.2
Senaldi, L.3
Zarek, P.E.4
Horton, M.5
Powell, J.D.6
-
116
-
-
33748416499
-
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
-
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New Engl J Med 2006; 355: 1018-1028.
-
(2006)
New Engl J Med
, vol.355
, pp. 1018-1028
-
-
Suntharalingam, G.1
Perry, M.R.2
Ward, S.3
Brett, S.J.4
Castello-Cortes, A.5
Brunner, M.D.6
-
117
-
-
34249677845
-
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
-
Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559.
-
(2007)
Nat Med
, vol.13
, pp. 552-559
-
-
Kanzler, H.1
Barrat, F.J.2
Hessel, E.M.3
Coffman, R.L.4
-
118
-
-
33745946911
-
Therapeutic potential of Toll-like receptor 9 activation
-
Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 471-484
-
-
Krieg, A.M.1
-
119
-
-
34547779420
-
Clinical setbacks for toll-like receptor 9 agonists in cancer
-
Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 2007; 25: 825-826.
-
(2007)
Nat Biotechnol
, vol.25
, pp. 825-826
-
-
Schmidt, C.1
-
120
-
-
0023092034
-
Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer
-
Watanabe Y, Iwa T. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Biol Response Mod 1987; 6: 169-180.
-
(1987)
J Biol Response Mod
, vol.6
, pp. 169-180
-
-
Watanabe, Y.1
Iwa, T.2
-
121
-
-
0027282550
-
Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma
-
Kikkawa F, Kawai M, Oguchi H, Kojima M, Ishikawa H, Iwata M et al. Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur J Cancer 1993; 29A: 1542-1546.
-
(1993)
Eur J Cancer
, vol.29 A
, pp. 1542-1546
-
-
Kikkawa, F.1
Kawai, M.2
Oguchi, H.3
Kojima, M.4
Ishikawa, H.5
Iwata, M.6
-
122
-
-
77952540334
-
Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: Clinical results
-
Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2010; 667: 111-123.
-
(2010)
Adv Exp Med Biol
, vol.667
, pp. 111-123
-
-
Cluff, C.W.1
-
123
-
-
84876238309
-
TLR3 agonists and proinflammatory antitumor activities
-
Sharma S, Zhu L, Davoodi M, Harris-White M, Lee St JM, John M et al. TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets 2013; 17: 481-483.
-
(2013)
Expert Opin Ther Targets
, vol.17
, pp. 481-483
-
-
Sharma, S.1
Zhu, L.2
Davoodi, M.3
Harris-White, M.4
Lee St, J.M.5
John, M.6
-
124
-
-
14644390867
-
Rapid and strong human CD8\+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
-
Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F et al. Rapid and strong human CD8\+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-746.
-
(2005)
J Clin Invest
, vol.115
, pp. 739-746
-
-
Speiser, D.E.1
Lienard, D.2
Rufer, N.3
Rubio-Godoy, V.4
Rimoldi, D.5
Lejeune, F.6
-
125
-
-
2442452552
-
CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction
-
Garbi N, Arnold B, Gordon S, Hammerling GJ, Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 2004; 172: 5861-5869.
-
(2004)
J Immunol
, vol.172
, pp. 5861-5869
-
-
Garbi, N.1
Arnold, B.2
Gordon, S.3
Hammerling, G.J.4
Ganss, R.5
-
126
-
-
33847080492
-
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors
-
Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007; 67: 1326-1334.
-
(2007)
Cancer Res
, vol.67
, pp. 1326-1334
-
-
Nava-Parada, P.1
Forni, G.2
Knutson, K.L.3
Pease, L.R.4
Celis, E.5
-
127
-
-
44749088349
-
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics
-
Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008; 180: 3797-3806.
-
(2008)
J Immunol
, vol.180
, pp. 3797-3806
-
-
Jarnicki, A.G.1
Conroy, H.2
Brereton, C.3
Donnelly, G.4
Toomey, D.5
Walsh, K.6
-
128
-
-
33744947314
-
Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice
-
Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 2006; 66: 5427-5435.
-
(2006)
Cancer Res
, vol.66
, pp. 5427-5435
-
-
Tormo, D.1
Ferrer, A.2
Bosch, P.3
Gaffal, E.4
Basner-Tschakarjan, E.5
Wenzel, J.6
-
129
-
-
0037436119
-
Toll pathway-dependent blockade of CD4\+CD25\+ T cell-mediated suppression by dendritic cells
-
Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4\+CD25\+ T cell-mediated suppression by dendritic cells. Science 2003; 299: 1033-1036.
-
(2003)
Science
, vol.299
, pp. 1033-1036
-
-
Pasare, C.1
Medzhitov, R.2
-
130
-
-
23944509107
-
Toll-like receptor 8-mediated reversal of CD4\+ regulatory T cell function
-
Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T et al. Toll-like receptor 8-mediated reversal of CD4\+ regulatory T cell function. Science 2005; 309: 1380-1384.
-
(2005)
Science
, vol.309
, pp. 1380-1384
-
-
Peng, G.1
Guo, Z.2
Kiniwa, Y.3
Voo, K.S.4
Peng, W.5
Fu, T.6
-
131
-
-
2442655250
-
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance
-
Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5: 508-515.
-
(2004)
Nat Immunol
, vol.5
, pp. 508-515
-
-
Yang, Y.1
Huang, C.T.2
Huang, X.3
Pardoll, D.M.4
-
132
-
-
84880865534
-
TAMable tumor-associated macrophages in response to innate RNA sensing
-
Seya T, Shime H, Matsumoto M. TAMable tumor-associated macrophages in response to innate RNA sensing. Oncoimmunology 2012; 1: 1000-1001.
-
(2012)
Oncoimmunology
, vol.1
, pp. 1000-1001
-
-
Seya, T.1
Shime, H.2
Matsumoto, M.3
-
133
-
-
84857136783
-
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors
-
Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 2012; 109: 2066-2071.
-
(2012)
Proc Natl Acad Sci USA
, vol.109
, pp. 2066-2071
-
-
Shime, H.1
Matsumoto, M.2
Oshiumi, H.3
Tanaka, S.4
Nakane, A.5
Iwakura, Y.6
-
134
-
-
33745809515
-
Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides
-
Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int Rev Immunol 2006; 25: 183-213.
-
(2006)
Int Rev Immunol
, vol.25
, pp. 183-213
-
-
Wilson, H.L.1
Dar, A.2
Napper, S.K.3
Marianela Lopez, A.4
Babiuk, L.A.5
Mutwiri, G.K.6
-
135
-
-
0242303573
-
Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides
-
Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener RP, Schmidt-Weber CB et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003; 33: 2717-2726.
-
(2003)
Eur J Immunol
, vol.33
, pp. 2717-2726
-
-
Akdis, C.A.1
Kussebi, F.2
Pulendran, B.3
Akdis, M.4
Lauener, R.P.5
Schmidt-Weber, C.B.6
-
136
-
-
84856558003
-
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma\+IL-17\+ polyfunctional T cells that mediate rejection of murine tumors
-
Marshall NA, Galvin KC, Corcoran AM, Boon L, Higgs R, Mills KH. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma\+IL-17\+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res 2012; 72: 581-591.
-
(2012)
Cancer Res
, vol.72
, pp. 581-591
-
-
Marshall, N.A.1
Galvin, K.C.2
Corcoran, A.M.3
Boon, L.4
Higgs, R.5
Mills, K.H.6
-
137
-
-
37849046096
-
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
-
Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008; 27: 168-180.
-
(2008)
Oncogene
, vol.27
, pp. 168-180
-
-
Conroy, H.1
Marshall, N.A.2
Mills, K.H.3
-
138
-
-
84860828384
-
Gene silencing of TGF-beta1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumorassociated regulatory T cells
-
Conroy H, Galvin KC, Higgins SC, Mills KH. Gene silencing of TGF-beta1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumorassociated regulatory T cells. Cancer immunol Immunother 2012; 61: 425-431.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 425-431
-
-
Conroy, H.1
Galvin, K.C.2
Higgins, S.C.3
Mills, K.H.4
-
139
-
-
84880936480
-
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
-
Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2013; 2: e22246.
-
(2013)
Oncoimmunology
, vol.2
, pp. e22246
-
-
Walter, S.1
Weinschenk, T.2
Reinhardt, C.3
Singh-Jasuja, H.4
-
140
-
-
34547630506
-
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model
-
Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007; 67: 7477-7486.
-
(2007)
Cancer Res
, vol.67
, pp. 7477-7486
-
-
Ko, H.J.1
Kim, Y.J.2
Kim, Y.S.3
Chang, W.S.4
Ko, S.Y.5
Chang, S.Y.6
-
141
-
-
84876783562
-
Restoring Immune Function of Tumor-Specific CD4\+ T Cells during Recurrence of Melanoma
-
Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A et al. Restoring Immune Function of Tumor-Specific CD4\+ T Cells during Recurrence of Melanoma. J Immunol 2013; 190: 4899-4909.
-
(2013)
J Immunol
, vol.190
, pp. 4899-4909
-
-
Goding, S.R.1
Wilson, K.A.2
Xie, Y.3
Harris, K.M.4
Baxi, A.5
Akpinarli, A.6
-
142
-
-
84879777241
-
Nivolumab plus Ipilimumab in Advanced Melanoma
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al. Nivolumab plus Ipilimumab in Advanced Melanoma. New Engl J Med 2013; 369: 122-133.
-
(2013)
New Engl J Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
-
143
-
-
84876248304
-
Endocrine side effects induced by immune checkpoint inhibitors
-
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocr Metab 2013; 98: 1361-1375.
-
(2013)
J Clin Endocr Metab
, vol.98
, pp. 1361-1375
-
-
Corsello, S.M.1
Barnabei, A.2
Marchetti, P.3
De Vecchis, L.4
Salvatori, R.5
Torino, F.6
|